Total intravenous anaesthesia (TIVA) & target-controlled infusion
Anaesthetic technique · Perioperative & Anaesthesia
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Maintenance of anaesthesia using intravenous agents (usually propofol with an opioid) delivered by target-controlled infusion (TCI) pumps that model plasma or effect-site concentration. Indications include tubeless/shared-airway surgery, MH susceptibility, PONV reduction, neuromonitoring and transfers.
Red flags
- Rising depth-monitor index or clinical signs of lightness during paralysis (risk of awareness)
- Infusion site swelling, resistance or disconnection — drug not reaching the patient
- Profound unexplained hypotension suggesting relative overdose
- Propofol infusion syndrome features on prolonged high-dose ICU infusions
Assessment
Differential diagnosis
- Awareness due to interrupted/insufficient infusion (lightness)
- Overdose/relative overdose causing hypotension
- Pump malfunction, line disconnection or tissued cannula
- Pharmacokinetic variability — elderly, obese, low cardiac output
- Confusion with volatile technique needs (MH risk, scavenging)
Investigations
- Continuous processed EEG (depth of anaesthesia) monitoring — strongly recommended when neuromuscular blockade is used
- Visual confirmation of a patent, visible IV line dedicated to the TIVA infusion
- Haemodynamic monitoring (invasive arterial line for major cases)
- Infusion pump data log / TCI model and target concentration display
Management
- Select an appropriate TCI model: Marsh or Schnider for propofol; adjust for age and weight (use lean/adjusted body weight appropriately)
- Site a dedicated, visible cannula with an antireflux and antisiphon valve; keep the infusion site in view
- Induce to effect-site target (e.g. propofol effect-site 4-6 microgram/mL) with a remifentanil TCI/opioid co-administration
- Apply processed EEG monitoring and titrate to target index while correlating with clinical signs
- Maintain the infusion continuously — never pause for transfer without a plan; watch for disconnection
- Titrate to surgical stimulus and haemodynamics; treat hypotension with fluids/vasopressors rather than abrupt large dose cuts that risk awareness
- At emergence, stop infusions and allow context-sensitive decrement; ensure adequate analgesia established before remifentanil stops
- Document infusion targets, total doses and depth-monitoring values
Drugs & doses
Propofol 1% or 2% — TCI effect-site target 4-6 microgram/mL (Schnider), titrated to depth monitor and clinical response
Remifentanil — TCI effect-site target 2-6 ng/mL, titrated to stimulus (short context-sensitive half-time)
Alternative opioid — Fentanyl 1-3 microgram/kg IV boluses if remifentanil not used
Lidocaine 0.5-1 mg/kg IV at induction to reduce propofol injection pain
Disposition
Routine recovery in PACU with standard monitoring; depth-monitor and infusion documentation retained, and awareness concerns followed up per local AAGA pathway.
Complications & pitfalls
- Accidental awareness under general anaesthesia from infusion failure
- Haemodynamic instability/hypotension
- Extravasation and failure of drug delivery
- Delayed emergence with inappropriate high targets
- Propofol-related infusion syndrome (prolonged, high-dose use)
Exam pearls
- Keep the infusion line and cannula visible at all times — a hidden tissued cannula is a leading cause of awareness
- TCI predicts, it does not measure — use processed EEG, especially when neuromuscular blockade masks movement
- Remifentanil offloads propofol requirement but offers no residual analgesia; establish longer-acting analgesia before stopping it
- TIVA is the technique of choice for MH-susceptible patients and reduces PONV versus volatile
- Antireflux and antisiphon valves and a dedicated line prevent catastrophic bolus or backflow
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.